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Background: Few reports have specifically addressed the efficacy of drug-eluting stents for chronic kidney disease patients.
We sought to evaluate the effect of varying degrees of renal impairment on angiographic and clinical outcomes after treatment with sirolimus- or 
paclitaxel-eluting stents (SES and PES).
Methods: The subjects were 951 consecutive patients with drug-eluting stents.
In the drug-eluting stent era, our institution used only SES from May 2004 to April 2007 and only PES from May 2007 to February 2009.
All consecutive de novo patients (n=951, 1302lesions) treated with SES (SES-group; n=466) or PES (PES-group; n=485) between May 2004 and 
February 2010 were analysed.
According to estimated glomerular filtration rate (eGFR), all patients were stratified into 4 stages (stageI; 60≤eGFR, stageII; 30≤eGFR<60, stageIII; 
eGFR<30 ml/min/1.73m2, stageIV; hemodialysis).
The angiographic restenosis measured by quantitive coronary angiography at 8 months, and target-lesion revascularization (TLR) and major adverse 
cardiac events (MACE) at 1 year were compared between groups.
Results: The angiographic restenosis rate was significantly lower in SES-group than PES-group with stage II (5.9% versus 15.8%; p<0.001), and 
stage III (7.3% versus 16.7%, p<0.05). Similarly, TLR was significantly lower in SES-group with stage II (1.1% versus 4.8%; p<0.01) and stage III 
(3.6% versus 8.7%; p<0.05). In the SES group, the in-stent restenosis rate and the incidence of TLR were not significantly different (p=0.92, 0.72) 
between patients at each stage (excluding stage IV). In the PES group, however, in-stent restenosis rate were significantly different (p<0.01) between 
patients at each stage of CKD.There were no significant differences of MACE, regardless of renal function (log-rank = NS).
Conclusions: These data suggest that use of SES did not influence the in-stent restenosis rate and incidence of TLR, while use of PES had a 
negative impact along with the progression of renal impairment, although it did not influence the incidence of MACE.
